SAN DIEGO, May 21, 2018 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that data
from a post-hoc analysis of the 22-week Phase 2 clinical study for
its investigative drug candidate ralinepag, a next-generation,
oral, selective and potent prostacyclin receptor agonist in
development for the treatment of pulmonary arterial hypertension
(PAH), will be presented at the American Thoracic Society (ATS)
International Conference on May 23.
The meeting is taking place May 18-23
in San Diego, CA.
Dr. Hap Farber, Professor of Medicine and Director, Pulmonary
Hypertension Center, Boston
University/Boston Medical Center, will present an analysis
of the correlation between ralinepag plasma levels and improvements
in functional and hemodynamic parameters in patients with pulmonary
arterial hypertension (PAH).
Arena previously announced topline Phase 2 results for ralinepag
in PAH in which the primary efficacy analysis demonstrated a
statistically significant absolute change from baseline in
pulmonary vascular resistance compared to placebo. Ralinepag
also demonstrated numerical improvement in 6-minute walk distance
relative to placebo in patients on PAH specific background therapy.
Adverse events observed in the study were consistent with other
prostacyclin treatments for the management of PAH.
Presentation Details
Title: Ralinepag Plasma
Levels Correlate With Improvements in Functional and Hemodynamic
Parameters in Patients With Pulmonary Arterial Hypertension
(PAH)
When: Wednesday, May 23,
1:30 PM PDT
About Ralinepag
Ralinepag (APD811) is an oral,
next-generation, selective IP receptor agonist targeting the
prostacyclin pathway and intended for the treatment of pulmonary
arterial hypertension (PAH). Arena discovered and developed this
drug candidate internally. Ralinepag's potency on vasodilation,
inhibition of proliferation of vascular smooth muscle cells, and
inhibition of platelet aggregation, combined with an extended
half-life support its application as a potentially best-in-class
agent for the treatment of PAH. Ralinepag is an investigational
compound that is not approved for any use in any country.
About Arena Pharmaceuticals
Arena Pharmaceuticals is
focused on delivering novel, transformational medicines with
optimized pharmacology and pharmacokinetics to patients globally.
Arena's proprietary pipeline includes multiple potentially first-
or best-in-class programs with broad clinical utility. The most
advanced investigational clinical programs are ralinepag (APD811),
which will be commencing a Phase 3 program for pulmonary arterial
hypertension (PAH), and etrasimod (APD334), which will be
commencing a Phase 3 program for ulcerative colitis (UC) and a
program in Crohn's Disease (CD), and which has potential utility
for a broad range of immune and inflammatory conditions. Arena is
also evaluating olorinab (APD371) in Phase 2 for the treatment of
visceral pain associated with Crohn's disease, as well as other
drug candidates in earlier research and development stages.
In addition, Arena has several collaborations including Everest
Medicines Limited (ralinepag and etrasimod in Greater China and select Asian countries),
Axovant Sciences GmbH (nelotanserin - Phase 2), Boehringer
Ingelheim International GmbH (undisclosed target - preclinical),
Outpost Medicine, LLC (undisclosed target – preclinical), and Eisai
Co., Ltd. and Eisai Inc. (BELVIQ® - marketed
product).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. These forward-looking statements may be
accompanied by words such as "will," "potential," "look forward
to," "intended for," "potentially," "focused on," "designed to," or
words of similar meaning, or by the fact that they do not relate
strictly to historical or current facts. Such forward-looking
statements include, without limitation, statements about Arena's
upcoming presentation at the ATS International Conference;
ralinepag, including relating to its potential to be an effective
PAH treatment or best-in-class, the Phase 3 clinical program in
patients with PAH that is currently in development and potential
findings from that study; and Arena's programs (including their
first- or best-in-class potential), focus and collaborations. For
such statements, Arena claims the protection of the Private
Securities Litigation Reform Act of 1995. Actual events or results
may differ materially from Arena's expectations. Factors that could
cause actual results to differ materially from the forward-looking
statements include that clinical programs may not proceed at the
time or in the manner expected or at all; enrolling patients in our
ongoing and intended clinical trials is competitive and
challenging; results of clinical trials and other studies are
subject to different interpretations and may not be predictive of
future results; the timing and outcome of research, development and
regulatory review is uncertain; topline data may not accurately
reflect the complete results of a particular study or trial;
nonclinical and clinical data are voluminous and detailed, and
regulatory agencies may interpret or weigh the importance of data
differently and reach different conclusions than Arena or others,
request additional information, have additional recommendations or
change their guidance or requirements before or after approval;
risks related to unexpected or unfavorable new data; and risks
related to developing and commercializing drugs. Additional factors
that could cause actual results to differ materially from those
stated or implied by Arena's forward-looking statements are
disclosed in Arena's filings with the Securities and Exchange
Commission (SEC), including but not limited to our Annual Report on
Form 10-K for the year ended December 31,
2017, which was filed with the SEC on March 14, 2018. These forward-looking statements
represent Arena's judgment as of the time of this release. Arena
disclaims any intent or obligation to update these forward-looking
statements, other than as may be required under applicable law.
Corporate Contact:
Kevin R.
Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, M.D.
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original content with
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-announces-data-presentation-for-ralinepag-in-pulmonary-arterial-hypertension-at-the-american-thoracic-society-international-conference-300651503.html
SOURCE Arena Pharmaceuticals, Inc.